BELIEVE: Phase III Study of Luspatercept vs Placebo in Beta-Thalassemia

December 1-4, 2018; San Diego, California

Transfusion-dependent adults with beta-thalassemia who received luspatercept were more likely to achieve clinically meaningful reductions in transfusion burden compared with placebo.

Format: Microsoft PowerPoint (.ppt)
File Size: 196 KB
Released: December 4, 2018

Acknowledgements

Provided by the Annenberg Center for Health Sciences at Eisenhower.
ACHS Logo

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Celgene Corporation
Dova Pharmaceuticals, Inc.
Gilead Sciences
Incyte
Jazz Pharmaceuticals, Inc.
Novartis Pharmaceuticals Corporation
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs
Seattle Genetics
Takeda Oncology

Related Content

Experts highlight key studies being presented at the upcoming 2021 ESMO Congress in this commentary from Clinical Care Options (CCO)

person default Eva Ciruelos, MD, PhD Karim Fizazi, MD, PhD Eric Van Cutsem, MD, PhD person default Vamsidhar Velcheti, MD Released: September 15, 2021

Downloadable slideset updated with highlights of key gynecologic oncology studies presented at conferences throughout 2021, from Clinical Care Options (CCO)

Jubilee Brown, MD Melissa M. Hardesty, MD, MPH person default Alexandra Leary, MD, PhD Domenica Lorusso, MD, PhD Ursula Matulonis, MD David Scott Miller, MD, FACOG, FACS Released: September 15, 2021

Safety and efficacy analysis of larotrectinib in TRK fusion–positive lung cancer, from WCLC 2021 as reported by Clinical Care Options (CCO)

Released: September 15, 2021

Subgroup analysis of IMower010 trial evaluating adjuvant atezolizumab vs best supportive care in patients with resected stage IB-IIIA NSCLC after adjuvant chemotherapy, from WCLC 2021 as reported by Clinical Care Options (CCO)

Released: September 15, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue